Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease

Hanin Bogari, Asad E Patanwala, Richard Cosgrove, Michael Katz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction There is a lack of evidence regarding the need for thromboprophylaxis in hospitalized patients with liver disease. The purpose of this study was to evaluate the Padua Predictor Score (PPS) as a risk-stratification tool for the development of venous thromboembolism (VTE) in patients with chronic liver disease.

Methods This was a retrospective cohort study conducted in an academic medical center in the United States. Consecutive adult patients admitted with chronic liver disease were included. Patients were categorized into two groups based on whether they developed a VTE or not. The risk for VTE in each patient was evaluated using the Padua Predictor Score (PPS). Patients were risk stratified using the PPS score as high-risk (score ≥ 4) and low-risk (score < 4). The risk of VTE based on PPS categorization was evaluated using logistic regression.

Results A total of 163 patients with liver disease were included in the study cohort. Of these, 18 (11%) developed VTE. Mean PPS was significantly greater in the VTE group than the non-VTE group (5.8 ± 2.0 versus 3.0 ± 2.1, respectively; p < 0.001). In high-risk patients 22% (n = 16/72) developed VTE and in low-risk patients 2% (2/91) developed VTE (p < 0.001). High-risk patients were more likely to have VTE (OR 12.7, 95% CI 2.8 to 57.4, p = 0.001).

Conclusion The PPS is an effective risk assessment tool for VTE in patients hospitalized with chronic liver disease.

Original languageEnglish (US)
Pages (from-to)1220-1223
Number of pages4
JournalThrombosis Research
Volume134
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Venous Thromboembolism
Liver Diseases
Chronic Disease
Pharmacology
Cohort Studies
Thromboembolism
Retrospective Studies
Logistic Models

Keywords

  • Anticoagulants
  • Heparin
  • Liver cirrhosis
  • Liver diseases
  • Thromboembolism
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease. / Bogari, Hanin; Patanwala, Asad E; Cosgrove, Richard; Katz, Michael.

In: Thrombosis Research, Vol. 134, No. 6, 01.12.2014, p. 1220-1223.

Research output: Contribution to journalArticle

@article{e8232d0c789442e0b6449307a2edd53b,
title = "Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease",
abstract = "Introduction There is a lack of evidence regarding the need for thromboprophylaxis in hospitalized patients with liver disease. The purpose of this study was to evaluate the Padua Predictor Score (PPS) as a risk-stratification tool for the development of venous thromboembolism (VTE) in patients with chronic liver disease.Methods This was a retrospective cohort study conducted in an academic medical center in the United States. Consecutive adult patients admitted with chronic liver disease were included. Patients were categorized into two groups based on whether they developed a VTE or not. The risk for VTE in each patient was evaluated using the Padua Predictor Score (PPS). Patients were risk stratified using the PPS score as high-risk (score ≥ 4) and low-risk (score < 4). The risk of VTE based on PPS categorization was evaluated using logistic regression.Results A total of 163 patients with liver disease were included in the study cohort. Of these, 18 (11{\%}) developed VTE. Mean PPS was significantly greater in the VTE group than the non-VTE group (5.8 ± 2.0 versus 3.0 ± 2.1, respectively; p < 0.001). In high-risk patients 22{\%} (n = 16/72) developed VTE and in low-risk patients 2{\%} (2/91) developed VTE (p < 0.001). High-risk patients were more likely to have VTE (OR 12.7, 95{\%} CI 2.8 to 57.4, p = 0.001).Conclusion The PPS is an effective risk assessment tool for VTE in patients hospitalized with chronic liver disease.",
keywords = "Anticoagulants, Heparin, Liver cirrhosis, Liver diseases, Thromboembolism, Venous thromboembolism",
author = "Hanin Bogari and Patanwala, {Asad E} and Richard Cosgrove and Michael Katz",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.thromres.2014.09.031",
language = "English (US)",
volume = "134",
pages = "1220--1223",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease

AU - Bogari, Hanin

AU - Patanwala, Asad E

AU - Cosgrove, Richard

AU - Katz, Michael

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Introduction There is a lack of evidence regarding the need for thromboprophylaxis in hospitalized patients with liver disease. The purpose of this study was to evaluate the Padua Predictor Score (PPS) as a risk-stratification tool for the development of venous thromboembolism (VTE) in patients with chronic liver disease.Methods This was a retrospective cohort study conducted in an academic medical center in the United States. Consecutive adult patients admitted with chronic liver disease were included. Patients were categorized into two groups based on whether they developed a VTE or not. The risk for VTE in each patient was evaluated using the Padua Predictor Score (PPS). Patients were risk stratified using the PPS score as high-risk (score ≥ 4) and low-risk (score < 4). The risk of VTE based on PPS categorization was evaluated using logistic regression.Results A total of 163 patients with liver disease were included in the study cohort. Of these, 18 (11%) developed VTE. Mean PPS was significantly greater in the VTE group than the non-VTE group (5.8 ± 2.0 versus 3.0 ± 2.1, respectively; p < 0.001). In high-risk patients 22% (n = 16/72) developed VTE and in low-risk patients 2% (2/91) developed VTE (p < 0.001). High-risk patients were more likely to have VTE (OR 12.7, 95% CI 2.8 to 57.4, p = 0.001).Conclusion The PPS is an effective risk assessment tool for VTE in patients hospitalized with chronic liver disease.

AB - Introduction There is a lack of evidence regarding the need for thromboprophylaxis in hospitalized patients with liver disease. The purpose of this study was to evaluate the Padua Predictor Score (PPS) as a risk-stratification tool for the development of venous thromboembolism (VTE) in patients with chronic liver disease.Methods This was a retrospective cohort study conducted in an academic medical center in the United States. Consecutive adult patients admitted with chronic liver disease were included. Patients were categorized into two groups based on whether they developed a VTE or not. The risk for VTE in each patient was evaluated using the Padua Predictor Score (PPS). Patients were risk stratified using the PPS score as high-risk (score ≥ 4) and low-risk (score < 4). The risk of VTE based on PPS categorization was evaluated using logistic regression.Results A total of 163 patients with liver disease were included in the study cohort. Of these, 18 (11%) developed VTE. Mean PPS was significantly greater in the VTE group than the non-VTE group (5.8 ± 2.0 versus 3.0 ± 2.1, respectively; p < 0.001). In high-risk patients 22% (n = 16/72) developed VTE and in low-risk patients 2% (2/91) developed VTE (p < 0.001). High-risk patients were more likely to have VTE (OR 12.7, 95% CI 2.8 to 57.4, p = 0.001).Conclusion The PPS is an effective risk assessment tool for VTE in patients hospitalized with chronic liver disease.

KW - Anticoagulants

KW - Heparin

KW - Liver cirrhosis

KW - Liver diseases

KW - Thromboembolism

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84916209535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916209535&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2014.09.031

DO - 10.1016/j.thromres.2014.09.031

M3 - Article

VL - 134

SP - 1220

EP - 1223

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -